Do analysts prefer AGPU or POAI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Axe Compute 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Predictive Oncology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts recommend TCX or POAI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tucows 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Predictive Oncology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts prefer POAI or VVPR?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Predictive Oncology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Vivopower International 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings & valuation, POAI or VVPR?

Predictive Oncology has higher revenue and earnings than Vivopower International. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Predictive Oncology $1.66M 19.96 -$12.66M -$13.50 N/A Vivopower International $61K 796.80 -$12.79M N/A N/A

Which has better earnings & valuation, VIVO or POAI?

Predictive Oncology has higher revenue and earnings than VivoPower PLC Ordinary Shares. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio VivoPower PLC Ordinary Shares $60K 818.63 -$12.79M N/A N/A Predictive Oncology $1.66M 19.96 -$12.66M -$13.50 N/A

Predictive Oncology (POAI) Competitors

$9.79 +0.34 (+3.60%)

As of 09/2/2026

Compare

POAI vs. AGPU, TCX, CHRN, VVPR, and VIVO

Should you buy Predictive Oncology stock or one of its competitors? Predictive Oncology's main competitors and comparable companies include Axe Compute (AGPU), Tucows (TCX), ChronoScale Corporation Common Stock (CHRN), Vivopower International (VVPR), and VivoPower PLC Ordinary Shares (VIVO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "internet services & infrastructure" industry.

How does Predictive Oncology compare to Axe Compute?

Axe Compute (NASDAQ:AGPU) and Predictive Oncology (NASDAQ:POAI) are both small-cap technology companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, analyst recommendations, institutional ownership, media sentiment, valuation, earnings and profitability.

In the previous week, Axe Compute's average media sentiment score of 0.00 equaled Predictive Oncology'saverage media sentiment score.

Company	Overall Sentiment
Axe Compute	Neutral
Predictive Oncology	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Axe Compute	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Predictive Oncology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Predictive Oncology has higher revenue and earnings than Axe Compute. Axe Compute is trading at a lower price-to-earnings ratio than Predictive Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Axe Compute	$120K	954.24	-$233.10M	-$5.75	N/A
Predictive Oncology	$1.66M	19.96	-$12.66M	-$13.50	N/A

Axe Compute has a beta of 3.47, indicating that its stock price is 247% more volatile than the broader market. Comparatively, Predictive Oncology has a beta of 1.35, indicating that its stock price is 35% more volatile than the broader market.

9.0% of Axe Compute shares are held by institutional investors. Comparatively, 9.0% of Predictive Oncology shares are held by institutional investors. 1.2% of Axe Compute shares are held by company insiders. Comparatively, 1.2% of Predictive Oncology shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Predictive Oncology has a net margin of -5,065.23% compared to Axe Compute's net margin of -7,769.61%. Predictive Oncology's return on equity of -732.73% beat Axe Compute's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Axe Compute	-7,769.61%	-1,606.56%	-355.39%
Predictive Oncology	-5,065.23%	-732.73%	-235.55%

Summary

Predictive Oncology beats Axe Compute on 6 of the 10 factors compared between the two stocks.

How does Predictive Oncology compare to Tucows?

Tucows (NASDAQ:TCX) and Predictive Oncology (NASDAQ:POAI) are both small-cap technology companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, media sentiment, risk, dividends, analyst recommendations, earnings and profitability.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tucows	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Predictive Oncology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Tucows has a beta of 0.85, meaning that its stock price is 15% less volatile than the broader market. Comparatively, Predictive Oncology has a beta of 1.35, meaning that its stock price is 35% more volatile than the broader market.

Predictive Oncology has lower revenue, but higher earnings than Tucows. Tucows is trading at a lower price-to-earnings ratio than Predictive Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tucows	$390.30M	0.31	-$75.82M	-$7.53	N/A
Predictive Oncology	$1.66M	19.96	-$12.66M	-$13.50	N/A

73.6% of Tucows shares are owned by institutional investors. Comparatively, 9.0% of Predictive Oncology shares are owned by institutional investors. 8.4% of Tucows shares are owned by insiders. Comparatively, 1.2% of Predictive Oncology shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Tucows' average media sentiment score of 0.00 equaled Predictive Oncology'saverage media sentiment score.

Company	Overall Sentiment
Tucows	Neutral
Predictive Oncology	Neutral

Tucows has a net margin of -21.20% compared to Predictive Oncology's net margin of -5,065.23%. Tucows' return on equity of 0.00% beat Predictive Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tucows	-21.20%	N/A	-9.48%
Predictive Oncology	-5,065.23%	-732.73%	-235.55%

Summary

Tucows beats Predictive Oncology on 7 of the 11 factors compared between the two stocks.

How does Predictive Oncology compare to ChronoScale Corporation Common Stock?

ChronoScale Corporation Common Stock (NASDAQ:CHRN) and Predictive Oncology (NASDAQ:POAI) are both technology companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, earnings, valuation, media sentiment, risk, analyst recommendations, profitability and institutional ownership.

ChronoScale Corporation Common Stock has a net margin of -135.66% compared to Predictive Oncology's net margin of -5,065.23%. ChronoScale Corporation Common Stock's return on equity of -197.81% beat Predictive Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ChronoScale Corporation Common Stock	-135.66%	-197.81%	-74.17%
Predictive Oncology	-5,065.23%	-732.73%	-235.55%

6.4% of ChronoScale Corporation Common Stock shares are owned by institutional investors. Comparatively, 9.0% of Predictive Oncology shares are owned by institutional investors. 6.9% of ChronoScale Corporation Common Stock shares are owned by company insiders. Comparatively, 1.2% of Predictive Oncology shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

ChronoScale Corporation Common Stock has a beta of 0.98, suggesting that its stock price is 2% less volatile than the broader market. Comparatively, Predictive Oncology has a beta of 1.35, suggesting that its stock price is 35% more volatile than the broader market.

ChronoScale Corporation Common Stock presently has a consensus price target of $6.00, suggesting a potential downside of 70.12%. Given ChronoScale Corporation Common Stock's stronger consensus rating and higher probable upside, analysts clearly believe ChronoScale Corporation Common Stock is more favorable than Predictive Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ChronoScale Corporation Common Stock	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Predictive Oncology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

ChronoScale Corporation Common Stock has higher revenue and earnings than Predictive Oncology. ChronoScale Corporation Common Stock is trading at a lower price-to-earnings ratio than Predictive Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ChronoScale Corporation Common Stock	$12.80M	228.47	-$11.69M	-$5.38	N/A
Predictive Oncology	$1.66M	19.96	-$12.66M	-$13.50	N/A

In the previous week, ChronoScale Corporation Common Stock had 2 more articles in the media than Predictive Oncology. MarketBeat recorded 2 mentions for ChronoScale Corporation Common Stock and 0 mentions for Predictive Oncology. ChronoScale Corporation Common Stock's average media sentiment score of 0.35 beat Predictive Oncology's score of 0.00 indicating that ChronoScale Corporation Common Stock is being referred to more favorably in the media.

Company	Overall Sentiment
ChronoScale Corporation Common Stock	Neutral
Predictive Oncology	Neutral

Summary

ChronoScale Corporation Common Stock beats Predictive Oncology on 12 of the 15 factors compared between the two stocks.

How does Predictive Oncology compare to Vivopower International?

Predictive Oncology (NASDAQ:POAI) and Vivopower International (NASDAQ:VVPR) are both small-cap technology companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, analyst recommendations, media sentiment, profitability, earnings, dividends and risk.

Predictive Oncology has higher revenue and earnings than Vivopower International.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Predictive Oncology	$1.66M	19.96	-$12.66M	-$13.50	N/A
Vivopower International	$61K	796.80	-$12.79M	N/A	N/A

In the previous week, Predictive Oncology's average media sentiment score of 0.00 equaled Vivopower International'saverage media sentiment score.

Company	Overall Sentiment
Predictive Oncology	Neutral
Vivopower International	Neutral

Vivopower International has a net margin of 0.00% compared to Predictive Oncology's net margin of -5,065.23%. Vivopower International's return on equity of 0.00% beat Predictive Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Predictive Oncology	-5,065.23%	-732.73%	-235.55%
Vivopower International	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Predictive Oncology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Vivopower International	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

9.0% of Predictive Oncology shares are held by institutional investors. Comparatively, 15.8% of Vivopower International shares are held by institutional investors. 1.2% of Predictive Oncology shares are held by company insiders. Comparatively, 9.1% of Vivopower International shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Predictive Oncology has a beta of 1.35, indicating that its stock price is 35% more volatile than the broader market. Comparatively, Vivopower International has a beta of -1.65, indicating that its stock price is 265% less volatile than the broader market.

Summary

Vivopower International beats Predictive Oncology on 6 of the 9 factors compared between the two stocks.

How does Predictive Oncology compare to VivoPower PLC Ordinary Shares?

VivoPower PLC Ordinary Shares (NASDAQ:VIVO) and Predictive Oncology (NASDAQ:POAI) are both small-cap technology companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, profitability, media sentiment, institutional ownership, risk, analyst recommendations, earnings and valuation.

In the previous week, VivoPower PLC Ordinary Shares' average media sentiment score of 0.67 beat Predictive Oncology's score of 0.00 indicating that VivoPower PLC Ordinary Shares is being referred to more favorably in the media.

Company	Overall Sentiment
VivoPower PLC Ordinary Shares	Positive
Predictive Oncology	Neutral

Predictive Oncology has higher revenue and earnings than VivoPower PLC Ordinary Shares.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
VivoPower PLC Ordinary Shares	$60K	818.63	-$12.79M	N/A	N/A
Predictive Oncology	$1.66M	19.96	-$12.66M	-$13.50	N/A

VivoPower PLC Ordinary Shares has a net margin of 0.00% compared to Predictive Oncology's net margin of -5,065.23%. VivoPower PLC Ordinary Shares' return on equity of 0.00% beat Predictive Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
VivoPower PLC Ordinary Shares	N/A	N/A	N/A
Predictive Oncology	-5,065.23%	-732.73%	-235.55%

VivoPower PLC Ordinary Shares has a beta of -0.65, meaning that its share price is 165% less volatile than the broader market. Comparatively, Predictive Oncology has a beta of 1.35, meaning that its share price is 35% more volatile than the broader market.

15.8% of VivoPower PLC Ordinary Shares shares are held by institutional investors. Comparatively, 9.0% of Predictive Oncology shares are held by institutional investors. 2.3% of VivoPower PLC Ordinary Shares shares are held by company insiders. Comparatively, 1.2% of Predictive Oncology shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

VivoPower PLC Ordinary Shares presently has a consensus price target of $10.00, indicating a potential upside of 155.10%. Given VivoPower PLC Ordinary Shares' stronger consensus rating and higher possible upside, equities research analysts plainly believe VivoPower PLC Ordinary Shares is more favorable than Predictive Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
VivoPower PLC Ordinary Shares	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Predictive Oncology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

VivoPower PLC Ordinary Shares beats Predictive Oncology on 10 of the 13 factors compared between the two stocks.

Get Predictive Oncology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

POAI vs. The Competition

Export

Metric	Predictive Oncology	IT Services Industry	Technology Sector	NASDAQ Exchange
Market Cap	$33.23M	$10.65B	$29.51B	$12.73B
Dividend Yield	N/A	2.77%	2.73%	8.86%
P/E Ratio	-0.73	14.28	75.76	25.38
Price / Sales	19.96	67.28	591.95	92.55
Price / Cash	N/A	41.84	47.32	52.26
Price / Book	-21.28	26.09	9.29	6.14
Net Income	-$12.66M	$268.46M	$678.51M	$349.01M
7 Day Performance	-5.50%	-0.92%	-0.87%	-0.27%
1 Month Performance	16.00%	-1.03%	-1.06%	0.68%
1 Year Performance	-28.64%	30.16%	185.84%	14.84%

Predictive Oncology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
POAI Predictive Oncology	0.0454 of 5 stars	$9.79 +3.6%	N/A	-27.5%	$33.23M	$1.66M	N/A	30
AGPU Axe Compute	0.2709 of 5 stars	$10.56 +2.0%	N/A	N/A	$122.32M	$120K	N/A	13
TCX Tucows	0.0528 of 5 stars	$8.86 -1.7%	N/A	-39.1%	$99.55M	$390.30M	N/A	1,000
CHRN ChronoScale Corporation Common Stock	0.922 of 5 stars	$21.59 +0.7%	$6.00 -72.2%	+374.7%	$76.86M	$12.80M	N/A	60	Positive News Gap Up
VVPR Vivopower International	0.0054 of 5 stars	$4.35 -0.2%	N/A	-20.8%	$54.49M	$61K	N/A	240

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:POAI) was last updated on 9/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Predictive Oncology (POAI) Competitors

POAI vs. AGPU, TCX, CHRN, VVPR, and VIVO

How does Predictive Oncology compare to Axe Compute?

Summary

How does Predictive Oncology compare to Tucows?

Summary

How does Predictive Oncology compare to ChronoScale Corporation Common Stock?

Summary

How does Predictive Oncology compare to Vivopower International?

Summary

How does Predictive Oncology compare to VivoPower PLC Ordinary Shares?

Summary

Media Sentiment Over Time

POAI vs. The Competition

Predictive Oncology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Predictive Oncology (POAI) Competitors

POAI vs. AGPU, TCX, CHRN, VVPR, and VIVO

How does Predictive Oncology compare to Axe Compute?

Does the media refer more to AGPU or POAI?

Do analysts prefer AGPU or POAI?

Which has preferable earnings & valuation, AGPU or POAI?

Which has more volatility and risk, AGPU or POAI?

Do insiders and institutionals have more ownership in AGPU or POAI?

Is AGPU or POAI more profitable?

Summary

How does Predictive Oncology compare to Tucows?

Do analysts recommend TCX or POAI?

Which has more risk and volatility, TCX or POAI?

Which has better earnings & valuation, TCX or POAI?

Do insiders & institutionals have more ownership in TCX or POAI?

Does the media refer more to TCX or POAI?

Is TCX or POAI more profitable?

Summary

How does Predictive Oncology compare to ChronoScale Corporation Common Stock?

Is CHRN or POAI more profitable?

Do insiders & institutionals hold more shares of CHRN or POAI?

Which has more risk and volatility, CHRN or POAI?

Do analysts recommend CHRN or POAI?

Which has higher earnings & valuation, CHRN or POAI?

Does the media refer more to CHRN or POAI?

Summary

How does Predictive Oncology compare to Vivopower International?

Which has better earnings & valuation, POAI or VVPR?

Does the media prefer POAI or VVPR?

Is POAI or VVPR more profitable?

Do analysts prefer POAI or VVPR?

Do insiders and institutionals have more ownership in POAI or VVPR?

Which has more risk & volatility, POAI or VVPR?

Summary

How does Predictive Oncology compare to VivoPower PLC Ordinary Shares?

Does the media refer more to VIVO or POAI?

Which has better earnings & valuation, VIVO or POAI?

Is VIVO or POAI more profitable?

Which has more volatility & risk, VIVO or POAI?

Do institutionals and insiders believe in VIVO or POAI?

Do analysts recommend VIVO or POAI?

Summary

Media Sentiment Over Time

POAI vs. The Competition

Predictive Oncology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools